Lyra Therapeutics Inc. (LYRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
LYRA POWR Grades
- LYRA scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.43% of US stocks.
- The strongest trend for LYRA is in Growth, which has been heading down over the past 61 days.
- LYRA's current lowest rank is in the Quality metric (where it is better than 8.61% of US stocks).
LYRA Stock Summary
- With a year-over-year growth in debt of -61.53%, LYRA THERAPEUTICS INC's debt growth rate surpasses merely 3.77% of about US stocks.
- As for revenue growth, note that LYRA's revenue has grown 11,492.86% over the past 12 months; that beats the revenue growth of 99.85% of US companies in our set.
- LYRA THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -161.94%, greater than the shareholder yield of only 3.81% of stocks in our set.
- Stocks that are quantitatively similar to LYRA, based on their financial statements, market capitalization, and price volatility, are VACC, AMLX, ORLA, RIVN, and CMRX.
- LYRA's SEC filings can be seen here. And to visit LYRA THERAPEUTICS INC's official web site, go to www.lyratherapeutics.com.
LYRA Valuation Summary
- LYRA's price/sales ratio is 38.3; this is 1915.79% higher than that of the median Healthcare stock.
- LYRA's price/sales ratio has moved NA NA over the prior 35 months.
Below are key valuation metrics over time for LYRA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LYRA | 2023-03-24 | 38.3 | 0.7 | -1.1 | 0.9 |
| LYRA | 2023-03-23 | 39.3 | 0.7 | -1.2 | 0.9 |
| LYRA | 2023-03-22 | 40.5 | 0.7 | -1.2 | 0.8 |
| LYRA | 2023-03-21 | 42.0 | 0.7 | -1.2 | 0.8 |
| LYRA | 2023-03-20 | 38.3 | 0.7 | -1.1 | 0.9 |
| LYRA | 2023-03-17 | 39.8 | 0.7 | -1.2 | 0.8 |
LYRA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LYRA has a Quality Grade of D, ranking ahead of 21.25% of graded US stocks.
- LYRA's asset turnover comes in at 0 -- ranking 171st of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows LYRA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | NA | -8.943 |
| 2021-03-31 | 0 | NA | -6.367 |
| 2020-12-31 | 0 | NA | -5.992 |
LYRA Price Target
For more insight on analysts targets of LYRA, see our LYRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $26.00 | Average Broker Recommendation | 1 (Strong Buy) |
LYRA Stock Price Chart Interactive Chart >
LYRA Price/Volume Stats
| Current price | $2.03 | 52-week high | $8.18 |
| Prev. close | $1.96 | 52-week low | $1.86 |
| Day low | $1.91 | Volume | 17,200 |
| Day high | $2.05 | Avg. volume | 33,990 |
| 50-day MA | $2.41 | Dividend yield | N/A |
| 200-day MA | $4.22 | Market Cap | 64.61M |
Lyra Therapeutics Inc. (LYRA) Company Bio
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer and is headquartered in Watertown, MA.
Latest LYRA News From Around the Web
Below are the latest news stories about LYRA THERAPEUTICS INC that investors may wish to consider to help them evaluate LYRA as an investment opportunity.
Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- -- Advancing In-House Manufacturing Capabilities to Prepare for Commercial Production -- WATERTOWN, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative th |
Estimating The Intrinsic Value Of Lyra Therapeutics, Inc. (NASDAQ:LYRA)Key Insights Lyra Therapeutics' estimated fair value is US$1.98 based on 2 Stage Free Cash Flow to Equity Lyra... |
Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
Lyra Therapeutics, Inc. (NASDAQ:LYRA) insiders placed bullish bets worth US$1.5m in the last 12 monthsMultiple insiders secured a larger position in Lyra Therapeutics, Inc. ( NASDAQ:LYRA ) shares over the last 12 months... |
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology OfficerLyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer Lyra Therapeutics CTO John Bishop, Ph.D. WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced the appointment of John Bishop, Ph.D., as Chief Technology Officer, effective February 27, 2023. Dr. Bisho |
LYRA Price Returns
| 1-mo | -14.71% |
| 3-mo | -35.35% |
| 6-mo | -59.48% |
| 1-year | -47.81% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -35.35% |
| 2022 | -27.98% |
| 2021 | -61.75% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...